Blog

DEEP RESEARCH · LIGACHEM BIO/JPM 2026

LigaChem Bio JPM 2026 Strategic Linkage Report

A review of how Eli Lilly's obesity, immunology, and ADC expansion may intersect with LigaChem's ConjuAll platform

Written: 2026-01-12 · Global biotech partnering/ADC platform view · Naver Blog original

Investment decisions are your responsibility. This research is not a recommendation to buy or sell.

0. Bottom line first

The key point is that no direct Lilly-LigaChem deal has been announced, but Lilly's need to internalize and broaden ADC capabilities can strategically intersect with LigaChem's ConjuAll and payload assets.

Official fact: The source says LigaChem was officially invited to JPM 2026 and cites a milestone from Ono Pharmaceutical, the USD 1.7 billion LCB84 deal with Janssen, and Iksuda's LCB14 ASCO GI 2026 data.

Interpretation: This is scenario analysis, not a claim that a partnership is already signed. It maps big-pharma demand against LigaChem's available technology supply.

Original image related to LigaChem Bio and the JPM Healthcare Conference
Strategic linkageLilly's needs and LigaChem's technology assets
LillyObesity, immunology, oncology expansion
ADCNectin-4, FRα, new targets
LigaChemConjuAll, payloads, LCB84
CDMOPossible Samsung Biologics link
No direct deal is announced, but the strategic overlap is clear.

1. What JPM 2026 says about pharma

The post frames the 44th J.P. Morgan Healthcare Conference in January 2026 as a turning point where precision medicine and broad metabolic-disease management both gained weight. Eli Lilly, now described as part of the USD 1 trillion market-cap club, is treated as the sector's directional signal.

Lilly's obesity strategy is summarized through oral small-molecule orforglipron, which may ease supply bottlenecks, and retatrutide, a triple agonist for GLP-1, GIP, and glucagon receptors.

Oral

Orforglipron

A non-peptide small-molecule oral therapy with an expected FDA decision in March 2026, positioned around scale manufacturing and lower cost.

Triple G

Retatrutide

The source says TRIUMPH-4 showed up to 28.7% weight loss in late 2025 and that Lilly aims to file in 2026.

Immunology

Ventyx acquisition

Read as an expansion into chronic inflammation and the NLRP3 inflammasome axis.

2. Lilly's dual ADC track

In oncology, Lilly is described as focusing on Nectin-4 and FRα ADCs while combining internal development with assets obtained through Emergence Therapeutics and Mablink.

Official fact: The post mentions competitive internal development using Nectin-4 candidates LY4052031 and LY4101174 in phase 1, and Mablink's PSARLink technology.

Interpretation: If PSARLink reduces ADC hydrophobicity, LigaChem's ConjuAll emphasizes plasma stability and intracellular tumor-specific cleavage. They point toward similar goals through different mechanisms, creating both competition and complementarity.

3. LigaChem's validation points

LigaChem appears as an official JPM 2026 invitee, and the milestone from Ono Pharmaceutical is presented as evidence that the platform has moved beyond discovery into development-stage validation.

AssetTarget/partnerMeaning in the source
LCB84Trop2 ADC / JanssenUSD 1.7 billion deal. A possible 2026 global-development option exercise is the key catalyst.
LCB97L1CAM ADC / OnoA potential first-in-class solid-tumor target and a pillar of Ono's next oncology portfolio.
LCB14HER2 ADC / IksudaASCO GI 2026 esophageal-cancer subgroup data with 80% CBR highlights post-Enhertu value.

4. Where Lilly and LigaChem could meet

Original image related to ADC platforms and partnering structure

The source explicitly states that no direct Lilly-LigaChem partnership had been announced as of January 2026. It still lays out three areas of potential fit.

  • Linkers: PSARLink and ConjuAll both target stability and homogeneity, but through different mechanisms.
  • Payload diversity: Lilly has linker assets, while LigaChem is described as owning next-generation PBD and Topo1 inhibitor payload technologies.
  • New targets: L1CAM, bispecific ADCs, and ABL Bio collaboration experience could match Lilly's interest in bispecific and solid-tumor expansion.

5. Samsung Biologics as a supply-chain variable

LigaChem's ADC collaboration with Samsung Biologics is interpreted as a one-stop development scenario from tech transfer to clinical material and commercial manufacturing. For a big pharma such as Lilly, that could reduce CDMO execution risk.

6. Monitoring points

  • Whether Janssen exercises the LCB84 option and whether the roughly USD 200 million payment materializes
  • LCB97 clinical entry and follow-on milestones from Ono Pharmaceutical
  • Whether LCB14 post-Enhertu data repeats across broader tumor settings
  • Signals that Lilly adds another external ADC platform
  • Whether LigaChem evolves from platform licensing company to global drug-development partner

Sources

Naver original